Medicines for Malaria Venture (MMV)

As malaria becomes more complex, treatment and prevention tools must become simpler. Progress against malaria has stalled. Meanwhile, drug resistance is rising, and climate change and conflict are...

malaria disease control prevention of mother to child transmission aids prevention microbicide

At the 79th World Health Assembly, MMV and partners hosted a side event where leaders across research, policy and global health convened to discuss what it will take to move new malaria tools from ...

malaria global health aids prevention rmnch pmtct

Every $1 invested in MMV-supported malaria medicines delivers an estimated $13 in health benefits.

malaria impact investing pmtct essential medicines microfinance

Dr Godwin Akpeko Dziwornu, a Senior Investigator at the Holistic Drug Discovery and Development (H3D) Centre, explains how the Drug Design for Global Health (dd4gh) platform can transform drug disc...

drug discovery global health drug development human resources for health aids prevention

Meet Wonder, a Ghanaian baby who was admitted to a hospital in Kumasi with #malaria at just 12 weeks old. He was treated with Coartem® Baby, the first antimalarial developed specifically for newb...

malaria premature infants pmtct prevention of mother to child transmission maternal and newborn health

For the first time, children living with relapsing malaria are receiving a single-dose cure, a breakthrough that could spare families repeated illness and help curb transmission in one of Brazil’s ...

malaria pmtct prevention of mother to child transmission neglected tropical diseases hiv prevention

Malaria is preventable and treatable, yet it still takes lives every day. Since 1999, MMV-supported medicines have helped treat or protect more than 1 billion people. That is real progress. But t...

malaria pmtct impact investing prevention of mother to child transmission pepfar

The landscape for the treatment of relapsing malaria has transformed considerably in recent years, due in part to the achievements of the Partnership for Vivax Elimination (PAVE). Led by MMV and ...

malaria pmtct pepfar aids prevention neglected tropical diseases

A new artificial intelligence (AI)-powered platform developed to accelerate drug discovery is now available free of charge to eligible global health researchers. Read the press release: bit.ly/48ap...

drug discovery artificial intelligence global health pharmaceutical research cgiar

Since 1999, MMV and partners have brought forward 19 antimalarials that have helped helped treat or protect 1.48 billion people. These include the first child-friendly artemisinin-based combination...

malaria essential medicines pmtct prevention of mother to child transmission aids prevention

Dr Max Jakobs, CEO of deepmirror, explains how the driving force behind dd4gh is the goal to get everyone using AI and machine learning for drug development and to make tools accessible where disea...

machine learning drug development drug discovery global health cgiar

MMV’s Director of Drug Discovery Benoit Laleu explains how dd4gh was built around two simple ideas: speed and access. Not just accelerating drug discovery, but doing so in a way that is inclusive o...

drug discovery global health drug development international drug monitoring vaccine development

Dr Jessica Thibaud, a postdoctoral researcher at Stellenbosch University working in antimalarial drug discovery, explains why she sees the Drug Design for Global Health (dd4gh) platform as a “pheno...

drug discovery global health drug development pharmaceutical research cgiar

At the 2025 ASTMH Annual Meeting, Paul Willis, MMV's VP Head of Early Development, joined the Alan J. Magill Malaria Eradication Symposium to share insights into using AI to support and accelerate ...

drug discovery global health malaria international drug monitoring cgiar

Professor Richard Amewu of the University of Ghana shares his perspective on the potential the Drug Design for Global Health (dd4gh) platform holds for drug discovery in Africa during a recent dd4g...

drug discovery global health aids prevention human resources for health drug development

maternal and newborn health maternal health services maternal health maternal welfare maternal mortality

2025 was a landmark year in the fight against malaria. From pioneering new treatments to expanding access and driving innovation through AI, MMV and partners made significant strides towards a mala...

malaria mrv pmtct post 2015 sdg5

The key takeaway from the 2025 World Malaria Report: #malaria drug resistance is an unmistakable threat. Since 2000, the #malaria community has prevented 2.3 billion cases and 14 million deaths...

malaria antimicrobial resistance pmtct prevention of mother to child transmission aids prevention

MMV is proud to announce its new partnership with South Korean biotechnology leader Shaperon to advance game-changing, nanobody treatments for malaria prevention. Nanobody therapeutics are a new g...

malaria microbicide mnch vaccine development prevention of mother to child transmission

MMV and Novartis have announced positive Phase 3 results for a novel malaria medicine, GanLum. If approved, GanLum would be the first major non-artemisinin-based innovation since 1999, with the p...